Revelation Biosciences Raises $4M in Public Offering

The latest update is out from Revelation Biosciences ( (REVB) ).

On May 28, 2025, Revelation Biosciences, Inc. entered into agreements for a public offering of its common stock and warrants, raising approximately $4 million in gross proceeds. The offering closed on May 29, 2025, with the company planning to use the funds for further development of its product candidates and general corporate purposes. The exercise price of the Class H Common Stock Warrants is $1.10 per share, and they will expire five years after issuance. The company has also agreed to certain restrictions on the sale of its securities for 90 days following the offering.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Spark’s Take on REVB Stock

According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.

Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.

To see Spark’s full report on REVB stock, click here.

More about Revelation Biosciences

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health. The company is developing its proprietary formulation, Gemini, for various applications including prevention of post-surgical infection, acute kidney injury, and treatment of chronic kidney disease.

Average Trading Volume: 919,196

Technical Sentiment Signal: Sell

Current Market Cap: $1.35M

For an in-depth examination of REVB stock, go to TipRanks’ Stock Analysis page.